Clinical trial
Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of…
NCT00440609 · Philip J. ferrone, M.D., Other · Completed
Key facts
| NCT number | NCT00440609 |
|---|---|
| Title | Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema |
| Official title | A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) With 0.5mg Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab |
| Lead sponsor | Philip J. ferrone, M.D., Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Clinically Significant Diabetic Macular Edema |
| Intervention type | Drug |
| Interventions | ranibizumab |
| Enrollment | 50 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Feb 27, 2007 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: